J Tan88
reacted to
$Mapletree Log Tr(M44U.SG$ My very last purchase at $1.30 to average down. No more bullets left for them anymore.
17
1
J Tan88
voted
As the cherry blossoms bloom, we're excited to unveil new horizons for our Singapore users in the Japanese stock market! 🗾🎌
Quick Vote 🗳️
Dive into Japan’s Markets 📊
Discover the diversity and opportunity within Japan's dynamic market landscape, from tech giants to traditional sectors! Feel free to share:
- What fascinates you about investing in Japan?
- Which sectors or companies catch your eye?
Share your thoughts and connect wi...
Quick Vote 🗳️
Dive into Japan’s Markets 📊
Discover the diversity and opportunity within Japan's dynamic market landscape, from tech giants to traditional sectors! Feel free to share:
- What fascinates you about investing in Japan?
- Which sectors or companies catch your eye?
Share your thoughts and connect wi...
38
39
J Tan88
liked
Humanoid robots are marvels of modern engineering, requiring a diverse array of components such as actuators for movement, sensors for environmental interaction, advanced control systems for decision-making, reliable power supplies, sophisticated chips for processing, cutting-edge software for operations, and communication systems to interact with the world around them. Each part is crucial, and theprecision...
68
1
J Tan88
liked
$Genius Group(GNS.US$ SINGAPORE, March 21, 2024 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE:GNS) ("Genius Group" or the "Company"), a leading AI-powered education group, announces updated financial guidance for the financial year ending December 31, 2024.
The updated guidance is over 100% higher than previously issued guidance as a result of the Company's expansion in operations following a series of recent transactions. The Company also has an accelerated go-to-market...
The updated guidance is over 100% higher than previously issued guidance as a result of the Company's expansion in operations following a series of recent transactions. The Company also has an accelerated go-to-market...
4
2
J Tan88
liked
$Pfizer(PFE.US$ $Novo-Nordisk A/S(NVO.US$ $Axsome Therapeutics(AXSM.US$ $Macrogenics(MGNX.US$
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...
16
5
J Tan88
liked and commented on
$Fusion Pharmaceuticals(FUSN.US$ loading zone 🛠️📈
1
1
J Tan88
liked
$Cybin(CYBN.US$
Read. Complain. Crime. They are shorting shares not available. Not producing them. Have to close by certain date. Force squeeze 🍋 A lot almost all lists have ran if not. They not only will they have to. SEC knows. Claims they Threshold List them. Suspecting manipulation. But MMs have been doing this. Ruining securities with synthetic shares that don't exist. Some have ran wild amounts as you've seen. Look at this please and read...
Read. Complain. Crime. They are shorting shares not available. Not producing them. Have to close by certain date. Force squeeze 🍋 A lot almost all lists have ran if not. They not only will they have to. SEC knows. Claims they Threshold List them. Suspecting manipulation. But MMs have been doing this. Ruining securities with synthetic shares that don't exist. Some have ran wild amounts as you've seen. Look at this please and read...
2
2
J Tan88
liked
4 FDA approvals last week
1 PDUFA event left in Feb 2024
Last week’s PDUFAs:
$AstraZeneca(AZN.US$ : Approved 2/16
⇒ Tagrisso (osimertinib) + chemotherapy
⇒ NSCLC
⇒ sNDA
⇒ PDUFA: Q1 2024
$Iovance Biotherapeutics(IOVA.US$ : Approved 2/16
⇒ AMTAGVI™ (lifileucel)
⇒ Melanoma
⇒ BLA
⇒ PDUFA: 02/24/24
$ROCHE HOLDING AG(RHHBY.US$ : Approved 2/16
⇒ Xolair® (omalizumab)
⇒ IgE-mediated food allergy
⇒ sBLA
⇒ PDUFA: Q1 2024
$IPSEY & $Merrimack Pharmaceuticals(MACK.US$ : Approved 2/13
⇒ ...
1 PDUFA event left in Feb 2024
Last week’s PDUFAs:
$AstraZeneca(AZN.US$ : Approved 2/16
⇒ Tagrisso (osimertinib) + chemotherapy
⇒ NSCLC
⇒ sNDA
⇒ PDUFA: Q1 2024
$Iovance Biotherapeutics(IOVA.US$ : Approved 2/16
⇒ AMTAGVI™ (lifileucel)
⇒ Melanoma
⇒ BLA
⇒ PDUFA: 02/24/24
$ROCHE HOLDING AG(RHHBY.US$ : Approved 2/16
⇒ Xolair® (omalizumab)
⇒ IgE-mediated food allergy
⇒ sBLA
⇒ PDUFA: Q1 2024
$IPSEY & $Merrimack Pharmaceuticals(MACK.US$ : Approved 2/13
⇒ ...
8
1
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,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)